Aim: Immune checkpoint inhibition (ICI) triggers immune-related adverse events (irAEs). The relevance of lipase elevation remains unclear. Patients and methods: Skin cancer patients with newly detected serum lipase elevation (at least twofold upper normal limit) or newly diagnosed type I diabetes mellitus upon ICI therapy were retrospectively collected at 14 German skin cancer centres. Results: We identified 68 patients with lipase elevation occurring after a median time of 19 (range 1–181) weeks on ICI, 15 (22%) thereof had symptoms consistent with pancreatitis. Forty-seven patients (73%) had other irAE, mainly colitis. Discontinuation (n = 24, 35%) or interruption (n = 26, 38%) of ICI resulted in decrease of lipase after reinduction of ICI lipase levels increased again in 12 of 24 patients. In 18 patients (27%), ICI was continued unchanged, and in 12 (67%) of them, lipase levels normalised. Twenty-two patients were identified with newly diagnosed type I diabetes mellitus related to ICI, and 12 (55%) thereof had also lipase elevation mainly shortly before or after the diagnosis of diabetes. Fourteen (64%) patients had other irAE, mainly thyroiditis. Irrespective of lipase elevation, patients frequently showed a rapid onset with ketoacidosis, decreased c-peptide, and strongly increased blood glucose levels. Conclusion: Increased serum lipase during ICI is often not associated with pancreatitis but with other irAE as possible cause. Therefore, it might be sufficient to regularly monitor blood glucose levels and perform further workup only in case of signs or symptoms of pancreatitis and/or exocrine pancreas insufficiency.

Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – a multicentre study of 90 patients from the german dermatooncology group / Grimmelmann, I.; Momma, M.; Zimmer, L.; Hassel, J. C.; Heinzerling, L.; Pfohler, C.; Loquai, C.; Ruini, C.; Utikal, J.; Thoms, K. -M.; Kahler, K. C.; Eigentler, T.; Herbst, R. A.; Meier, F.; Debus, D.; Berking, C.; Kochanek, C.; Ugurel, S.; Gutzmer, R.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 149:(2021), pp. 1-10. [10.1016/j.ejca.2021.02.017]

Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – a multicentre study of 90 patients from the german dermatooncology group

Ruini C.;
2021

Abstract

Aim: Immune checkpoint inhibition (ICI) triggers immune-related adverse events (irAEs). The relevance of lipase elevation remains unclear. Patients and methods: Skin cancer patients with newly detected serum lipase elevation (at least twofold upper normal limit) or newly diagnosed type I diabetes mellitus upon ICI therapy were retrospectively collected at 14 German skin cancer centres. Results: We identified 68 patients with lipase elevation occurring after a median time of 19 (range 1–181) weeks on ICI, 15 (22%) thereof had symptoms consistent with pancreatitis. Forty-seven patients (73%) had other irAE, mainly colitis. Discontinuation (n = 24, 35%) or interruption (n = 26, 38%) of ICI resulted in decrease of lipase after reinduction of ICI lipase levels increased again in 12 of 24 patients. In 18 patients (27%), ICI was continued unchanged, and in 12 (67%) of them, lipase levels normalised. Twenty-two patients were identified with newly diagnosed type I diabetes mellitus related to ICI, and 12 (55%) thereof had also lipase elevation mainly shortly before or after the diagnosis of diabetes. Fourteen (64%) patients had other irAE, mainly thyroiditis. Irrespective of lipase elevation, patients frequently showed a rapid onset with ketoacidosis, decreased c-peptide, and strongly increased blood glucose levels. Conclusion: Increased serum lipase during ICI is often not associated with pancreatitis but with other irAE as possible cause. Therefore, it might be sufficient to regularly monitor blood glucose levels and perform further workup only in case of signs or symptoms of pancreatitis and/or exocrine pancreas insufficiency.
2021
diabetes; diabetes mellitus; immune checkpoint inhibitors; immune-related adverse events; ipilimumab; lipase; nivolumab; pancreatitis; pd-1 inhibitor; pembrolizumab; adult; aged; aged; 80 and over; biomarkers; blood glucose; diabetes mellitus; type 1; exocrine pancreatic insufficiency; female; germany; humans; immune checkpoint inhibitors; lipase; male; melanoma; middle aged; pancreatitis; predictive value of tests; retrospective studies; skin neoplasms; time factors; treatment outcome; up-regulation; young adult
01 Pubblicazione su rivista::01a Articolo in rivista
Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – a multicentre study of 90 patients from the german dermatooncology group / Grimmelmann, I.; Momma, M.; Zimmer, L.; Hassel, J. C.; Heinzerling, L.; Pfohler, C.; Loquai, C.; Ruini, C.; Utikal, J.; Thoms, K. -M.; Kahler, K. C.; Eigentler, T.; Herbst, R. A.; Meier, F.; Debus, D.; Berking, C.; Kochanek, C.; Ugurel, S.; Gutzmer, R.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 149:(2021), pp. 1-10. [10.1016/j.ejca.2021.02.017]
File allegati a questo prodotto
File Dimensione Formato  
Grimmelmann_Lipase_2021.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 447.95 kB
Formato Adobe PDF
447.95 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1682141
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 13
social impact